#Israel #financial results #medical technology #Yokneam #InMode

InMode Ltd. Set to Release Q3 Financial Results

InMode Ltd. (Nasdaq: INMD), renowned for its cutting-edge medical technologies, is gearing up to disclose its financial performance for the third quarter of 2026. This announcement is scheduled for November 11, 2026, before the opening of the Nasdaq market. The company has unveiled its preliminary revenue expectations, indicating a robust financial standing amidst ongoing evaluations of strategic proposals.

Financial Performance Preview

InMode anticipates that its revenue for the third quarter will fall between a promising range of $91.8 million and $92.0 million. Furthermore, the company has reaffirmed its full-year revenue guidance for 2026, expecting to achieve an overall revenue between $365 million and $375 million. This consistency in their forecasts reflects the company's strategic confidence and operational robustness, despite some market fluctuations.

As the company prepares its comprehensive financial report, it has prioritized final adjustments and closing procedures. It's noteworthy that these preliminary results are unaudited and still subject to change, denoting the importance of careful assessments and reconciliations in financial reporting.

Strategic Development and Investor Relations

Adding another layer of complexity to the forthcoming financial results, InMode has indicated its Special Committee is currently examining a strategic proposal, which inherently influences its investor communication strategy. As a result, the company has decided against hosting an investor conference call or conducting meetings to discuss the third-quarter results. This strategic pause allows for a more focused analysis of their potential plans before engaging with stakeholders.

About InMode

InMode continues to lead the pharmaceutical industry as a prominent innovator, developing a diverse range of devices that utilize advanced radio frequency technology. By enhancing procedures and refining existing treatment techniques, InMode is at the forefront of minimally invasive medical technology.

The company's extensive product line serves various sectors of healthcare, including plastic surgery, dermatology, gynecology, otolaryngology, and ophthalmology. Their commitment to improving patient care is evident in their sustained investment in research and development, ensuring that their technologies remain at the cutting edge of medical science.

Anyone seeking further information about InMode's offerings or the upcoming financial results can visit their official website at www.inmodemd.com.

Looking Ahead

The upcoming release of InMode’s Q3 financial results is keenly awaited by investors and market analysts alike. While uncertainties can affect projections, InMode's historical performance and proactive management strategy lead many to maintain a positive outlook on its future trajectory.

As the market prepares for this announcement, stakeholders are advised to remain engaged with InMode's evolving narrative to understand how their innovative approaches continue to shape the landscape of medical technologies.